Such therapies include PI3K/AKT/mTOR inhibitors and AMPK activators (which inhibit the mTOR pathway), such as Metformin and Demethoxycurcumin) [2,55,56,57], PARP inhibitors (Olaparib, Talazoparib, Veliparib, Iniparib), mTOR inhibitors (Everolimus), pan-PI3K inhibitors (e.g., Buparlisib, Alpelisib, Pictilisib, Taselisib), CDK4/6 inhibitors (Palbociclib, Ribociclib, Abemaciclib), and other tumor-specific molecular target drugs (e.g., Deubiquitinases), and microRNAs (e.g., miRNA-200c, miRNA-21, miR-185-5p) [3,58,59,60]. The gene discussed is PIK3CA; the disease is neoplasm.